Rights Issue – Allotment of shares
Further to the Antisense Therapeutics (ASX:ANP) announcement of 7 December 2010 regarding the successful completion of the Company’s 1:2 renounceable Rights Issue, the Company would like to confirm that allotment of the Rights Issue securities has occurred.
Antisense Therapeutics’ MD and CEO Mark Diamond said, “We are very pleased to have successfully completed this Rights Issue. The new funding will be put to use immediately with the initiation of work on the formulation of ATL1103 compound into injectible product for use in human clinical trials of ATL1103. We would like to thank our existing shareholders and new investors in ANP for their support in the Rights Issue and we look forward to providing future updates on our progress.”
Download this document